RU2018135643A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018135643A3 RU2018135643A3 RU2018135643A RU2018135643A RU2018135643A3 RU 2018135643 A3 RU2018135643 A3 RU 2018135643A3 RU 2018135643 A RU2018135643 A RU 2018135643A RU 2018135643 A RU2018135643 A RU 2018135643A RU 2018135643 A3 RU2018135643 A3 RU 2018135643A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610165018.6 | 2016-03-22 | ||
| CN201610165018 | 2016-03-22 | ||
| PCT/CN2016/111717 WO2017161937A1 (zh) | 2016-03-22 | 2016-12-23 | Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018135643A RU2018135643A (ru) | 2020-04-22 |
| RU2018135643A3 true RU2018135643A3 (ru) | 2020-04-22 |
| RU2733412C2 RU2733412C2 (ru) | 2020-10-01 |
Family
ID=59899195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135643A RU2733412C2 (ru) | 2016-03-22 | 2016-12-23 | Поликристаллическая форма свободного основания или соли присоединения кислоты ингибитора egfr, способ её получения и применение |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10759782B2 (ru) |
| EP (1) | EP3434673B1 (ru) |
| JP (1) | JP7007287B2 (ru) |
| KR (1) | KR102765652B1 (ru) |
| CN (3) | CN108884072B (ru) |
| AU (1) | AU2016399168B2 (ru) |
| CA (1) | CA3016092A1 (ru) |
| ES (1) | ES2857805T3 (ru) |
| RU (1) | RU2733412C2 (ru) |
| TW (1) | TWI736570B (ru) |
| WO (1) | WO2017161937A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2857805T3 (es) * | 2016-03-22 | 2021-09-29 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Forma policristalina de base libre o sal ácida del inhibidor de EGFR, método de preparación y aplicación |
| CN110317265B (zh) * | 2018-03-28 | 2023-03-10 | 江苏豪森药业集团有限公司 | 比伐芦定晶型a及其制备方法 |
| WO2019218958A1 (zh) * | 2018-05-15 | 2019-11-21 | 江苏豪森药业集团有限公司 | 包含小分子egfr抑制剂的药物组合物及其制备方法 |
| TWI762784B (zh) * | 2018-05-23 | 2022-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 |
| CN110652514A (zh) * | 2018-06-29 | 2020-01-07 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制药用途 |
| TW202100150A (zh) * | 2019-03-04 | 2021-01-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 多靶點酪胺酸激酶抑制劑與egfr抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| CN111747950B (zh) * | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| CN113179640B (zh) * | 2019-11-26 | 2024-06-25 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| CN113679723B (zh) * | 2020-05-19 | 2024-11-05 | 蚌埠医学院 | Egfr抑制剂制备治疗乳腺癌药物的用途 |
| WO2022105882A1 (zh) * | 2020-11-19 | 2022-05-27 | 上海翰森生物医药科技有限公司 | 一种含吲哚类衍生物的盐、晶型及其制备方法和应用 |
| CN112457299B (zh) * | 2020-12-14 | 2021-12-17 | 江苏豪森药业集团有限公司 | Egfr抑制剂的纯化方法 |
| US20240199598A1 (en) * | 2021-04-12 | 2024-06-20 | Mitoimmune Therapeutics Inc. | Sulfate of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indole-7-amine, and novel crystal form thereof |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
| EA033733B1 (ru) * | 2011-07-27 | 2019-11-20 | Astrazeneca Ab | Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака, и промежуточные соединения для их получения |
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
| CN103819461B (zh) * | 2012-11-19 | 2016-06-15 | 齐鲁制药有限公司 | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 |
| CN104761544B (zh) * | 2014-01-03 | 2019-03-15 | 北京轩义医药科技有限公司 | Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂 |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| PT3157916T (pt) * | 2014-06-19 | 2019-03-25 | Ariad Pharma Inc | Compostos heteroarilo para inibição de cinase |
| CN104140418B (zh) * | 2014-08-15 | 2016-08-24 | 常州润诺生物科技有限公司 | 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途 |
| JP6691281B2 (ja) * | 2014-10-11 | 2020-04-28 | シャンハイ ハンソウ バイメディカル カンパニー リミテッド | Ｅｇｆｒ阻害薬、およびそれらの製造および応用 |
| CN104961731A (zh) * | 2015-02-05 | 2015-10-07 | 苏州晶云药物科技有限公司 | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 |
| ES2857805T3 (es) * | 2016-03-22 | 2021-09-29 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Forma policristalina de base libre o sal ácida del inhibidor de EGFR, método de preparación y aplicación |
-
2016
- 2016-12-23 ES ES16895281T patent/ES2857805T3/es active Active
- 2016-12-23 KR KR1020187029449A patent/KR102765652B1/ko active Active
- 2016-12-23 WO PCT/CN2016/111717 patent/WO2017161937A1/zh not_active Ceased
- 2016-12-23 JP JP2018547390A patent/JP7007287B2/ja active Active
- 2016-12-23 AU AU2016399168A patent/AU2016399168B2/en active Active
- 2016-12-23 CN CN201680081553.1A patent/CN108884072B/zh active Active
- 2016-12-23 EP EP16895281.0A patent/EP3434673B1/en active Active
- 2016-12-23 CN CN202011227541.XA patent/CN112645932B/zh active Active
- 2016-12-23 RU RU2018135643A patent/RU2733412C2/ru active
- 2016-12-23 CA CA3016092A patent/CA3016092A1/en active Pending
- 2016-12-23 US US16/085,117 patent/US10759782B2/en active Active
- 2016-12-23 CN CN202011227902.0A patent/CN112645933B/zh active Active
- 2016-12-30 TW TW105144164A patent/TWI736570B/zh active
-
2020
- 2020-08-06 US US16/986,687 patent/US11155534B2/en active Active
-
2021
- 2021-10-25 US US17/509,875 patent/US20220281847A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN108884072A (zh) | 2018-11-23 |
| US20190077791A1 (en) | 2019-03-14 |
| CN112645932B (zh) | 2022-01-14 |
| US20220281847A1 (en) | 2022-09-08 |
| EP3434673B1 (en) | 2021-02-17 |
| AU2016399168B2 (en) | 2021-01-21 |
| WO2017161937A1 (zh) | 2017-09-28 |
| RU2733412C2 (ru) | 2020-10-01 |
| HK1259142A1 (zh) | 2019-11-29 |
| US11155534B2 (en) | 2021-10-26 |
| CA3016092A1 (en) | 2017-09-28 |
| KR102765652B1 (ko) | 2025-02-11 |
| ES2857805T3 (es) | 2021-09-29 |
| KR20180131572A (ko) | 2018-12-10 |
| AU2016399168A1 (en) | 2018-10-25 |
| CN108884072B (zh) | 2020-12-22 |
| JP2019509290A (ja) | 2019-04-04 |
| US10759782B2 (en) | 2020-09-01 |
| RU2018135643A (ru) | 2020-04-22 |
| US20200361909A1 (en) | 2020-11-19 |
| EP3434673A4 (en) | 2019-08-07 |
| CN112645932A (zh) | 2021-04-13 |
| EP3434673A1 (en) | 2019-01-30 |
| JP7007287B2 (ja) | 2022-01-24 |
| CN112645933A (zh) | 2021-04-13 |
| TW201734006A (zh) | 2017-10-01 |
| TWI736570B (zh) | 2021-08-21 |
| CN112645933B (zh) | 2022-02-11 |